Investor's Business Daily on MSN28m
Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter BeatBiogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.
Jasper Therapeutics, Inc. (JSPR) stock has hit a 52-week low, trading at $4.99, down 21% in the past week alone. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback